CPRX — Catalyst Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$31.49
+$0.00 (+0.00%)
Catalyst Pharmaceuticals Inc (CPRX) is a biotechnology company listed on NASDAQ. It is led by Richard John Daly M.B.A., based in 355 Alhambra Circle, Coral Gables, FL, United States, 33134, with about 182 employees. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Latest reported CPRX revenue for 2025-09-30 was $148.4M. Net income was $161.6M. Revenue was up 1.2% from 2025-06-30 to 2025-09-30. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
Use this CPRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CPRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CPRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Catalyst Pharmaceuticals Inc even when a live quote feed is slow.
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX Key Statistics
Market Cap
$3.84B
Volume
15.51M
Previous Close
$31.49
Day Range
$31.48 – $31.50
P/E Ratio
18.15
P/B Ratio
3.79
EPS
$1.31
Revenue
$491.73M
Net Income
$163.89M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+23.5%
Profit Margin
33.3%
Employees
182
CPRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $491.73M | $398.20M | $214.20M | $140.83M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $163.89M | $71.41M | $83.08M | $39.48M |
| EPS (Diluted) | $1.31 | $0.63 | $0.75 | $0.37 |
Total Assets
$851.41M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$517.55M
Operating Cash Flow
$239.81M
Free Cash Flow
$0.00
Catalyst Pharmaceuticals Inc Company Information
- President, CEO & Director
- Richard John Daly M.B.A.
- Headquarters
- 355 Alhambra Circle, Coral Gables, FL, United States, 33134
- Website
- catalystpharma.com
- Phone
- 305 420 3200
- IPO / Founded
- 2006-11-08
- Sector
- Healthcare
- Industry
- Biotechnology